ClinicalTrials.gg

Program

stiripentol

Also written as “Stiripentol”, “Stiripentol Oral Capsule” and “Stiripentol capsule (Diacomit®)”.

Its studies are mostly in Primary hyperoxaluria type 1 · Epilepsies, Myoclonic · Epilepsies, Partial · Hyperoxaluria, Primary, led by Biocodex.

Furthest: phase 4, since May 16, 20225 company-led studies, 1 open or runningNext primary completion: Aug 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biocodex51 open or runningphase 4since May 16, 2022Jan 18, 2019Aug 2030phase 3 · NCT06465472

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 18, 2019First study: phase 2 study in Hyperoxaluria, PrimaryFirst studyNCT03819647 · 15 enrolled · France
  2. Mar 5, 2019Phase 1 study in Healthy VolunteersNCT03866928 · 14 enrolled · Belgium
  3. May 16, 2022Phase 4 study in Pharmacoresistant Focal EpilepsiesNCT05419180 · 52 enrolled · France
  4. Jun 3, 2024Phase 3 study in Primary hyperoxaluria type 1NCT06465472 · 42 planned · France
  5. Aug 29, 2025Phase 1 study in Epilepsies, MyoclonicNCT07176832 · 24 enrolled · France

Ahead

  1. Aug 2030Primary completion: phase 3 study in Primary hyperoxaluria type 1NCT06465472

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07176832Epilepsies, Myoclonic · France1CompletedAug 27, 202524
NCT06465472Primary hyperoxaluria type 1 · France3RecruitingAug 203042
NCT05419180Pharmacoresistant Focal Epilepsies · France4CompletedJun 13, 202452
NCT03866928Healthy Volunteers · Belgium1CompletedApr 5, 201914
NCT03819647Hyperoxaluria, Primary · France2CompletedDec 18, 202015

How it is read

Names in the registry

  • “Stiripentol”, 2 entries
  • “Stiripentol Oral Capsule”, 1 entry
  • “Stiripentol capsule (Diacomit®)”, 1 entry
  • “Stiripentol oral suspension (Diacomit®)”, 1 entry
  • “stiripentol (Diacomit)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.